PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

PALLIATIVE INTERFERON a 2A THERAPY FOR MALIGNANT RENAL TUMOURS AND ITS METASTASES
Article published in Urologia Polska 1997/50/2.

authors

Witold Cerski, Eugeniusz Miękoś, Zbigniew Jabłonowski
Klinika Urologii Wojskowej Akademii Medycznej w Łodzi
Kierownik: prof. dr hab. med. E. Miękoś

keywords

kidney renal cell carcinoma neoplasm metastasis ? interferon a 2a

summary

Objective. The effectiveness of interferon a 2a therapy (Roferon-A) in patients with
non-operating renal carcinoma with or without metastases was estimated in the
preliminary report.
Material and method. We have treated 7 patients with renal carcinoma. In 3 of them
the interferon therapy followed the non-radical nephrectomy (tumor exceeding Gerota's
fascia), and in 4 renal artery embolisation was performed before interferon therapy.
Patients received interferon monotherapy in 3 or 6 months cycles. Interferon was
applied in subcutaneous injections three times a week in doses growing from 3 to
maximally 18 MIU. The exact dose depends on the patients drug tolerance.
Flu-like symptoms were the common side effect in all the patients.
In all patients biochemical blood tests were performed every month. Ultrasonography,
chest X-ray film, CT of abdomen and renal scintigrąphy were performed every 3 months.
Results. In 6 patients no progression of the disease was found. One patient died 3
months after the therapy. The longest follow-up period is 28 months.
Conclusion. The interferon a 2a therapy (Roferon-A) seems to be encouraging.

references

  1. [1] Chouddhury, M., Efros, M., Mittelman, A.: Interferons and interleukins in
  2. metastatic renal cell carcinoma. Urology, 1993, 41, 67.
  3. [2] Ellerhorst, ]., Kilbourn, R., Amato, R., Zukiwski, A., Jones, E., Logothetis,
  4. C: Phase II trial of low dose y-interferon in metastatic renal cell carcinoma. J. Urol.,
  5. 1994,152, 841.
  6. [3] Fossa, S., Kramar, A., Droz, J.: Prognostic factors and survival in patients with
  7. metastatic renal cell carcinoma treated with chemotherapy or interferon alfa. Eur. J.
  8. Cancer, 1994, 30A, 1310.
  9. [4] Fossa, S., Jones, M., Johnson, R, Joffe, }., Holdener, E., Elson, R, Ritchie,
  10. A.: Interferon-alpha and survival in renal cell cancer. Brit. J. Urol., 1995, 76, 286
  11. [5] Goepel, M., Rubben, W.: Adjuyant therapy in renal cancer. World J. Urol., 1991,
  12. 9, 232.
  13. [6] Guinon, R, Yogelzang, N., Fremgen, A., Chimel, J., Sylvester, J.: Renal cell carci-
  14. noma: tumor size, stage and survival. J. Urol., 1995,153, 901.
  15. [7] Kernion, B., Sarna, G., Trinidada, A.: The treatment of renal cell carcinoma
  16. with human leukocyte alpha interferon. J. Urol, 1983,130,1063.
  17. [8] Niederle, N., von Wussow, R: Interferon. Praklinische und klinische befunde.
  18. Berlin 1990,1-45.
  19. [9] Oliver, R., Nethersell, A., Bottomley, }.: Unexplained spontaneos regression
  20. and a-interferon as treatment for metastatic renal carcinoma. Brit. J. Urol., 1989,
  21. 63,128.
  22. [10] Rinehart, J., Young, D., Laforge,}., Coluburn, D., Neidhart, J.: Phase I/II trial of
  23. recombinant gamma-interferon in patients with renal cell carcinoma: immunologic
  24. and biologic effects. J. Biol. Resp. Mod., 1987, 6,302.
  25. [11] Thiounn, N., Mathiot, C, Dorval, T, Flam, T. A., Tartour, E., Mosseri, V., Ze-
  26. rbib, M., Fridman, W. H., Debre, B.: Lack of efficacy oflow-dose subcutaneous
  27. recombinant interleukin-2 and interferon-a in the treatment of metastatic renal cell
  28. carcinoma. Brit. J. Urol., 1995, 75, 586.